{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:05:35Z","timestamp":1793387135234,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T01:12:40Z","timestamp":1714180360000},"page":"603-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations"],"prefix":"10.1016","volume":"23","author":[{"given":"Jonathan D.","family":"Cogen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jcf.2024.04.004_bib0001","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.04.004_bib0002","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/ppul.21442","article-title":"Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers","volume":"46","author":"Kraynack","year":"2011","journal-title":"Pediatr Pulmonol"},{"issue":"12","key":"10.1016\/j.jcf.2024.04.004_bib0003","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/ppul.25092","article-title":"Oral antibiotic prescribing patterns for treatment of pulmonary exacerbations in two large pediatric CF centers","volume":"55","author":"Hoppe","year":"2020","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0004","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcf.2017.04.005","article-title":"Standardized Treatment of Pulmonary Exacerbations (STOP) study: observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations","volume":"16","author":"Sanders","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2024.04.004_bib0005","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0006","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcf.2020.07.008","article-title":"Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0007","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2017.04.003","article-title":"Standardized treatment of pulmonary exacerbations (STOP) study: physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary exacerbations","volume":"16","author":"West","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"Suppl 2","key":"10.1016\/j.jcf.2024.04.004_bib0008","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(11)60012-X","article-title":"Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials","volume":"10","author":"Bilton","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0009","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1513\/AnnalsATS.201608-615OC","article-title":"Relationship of antibiotic treatment to recovery after acute FEV(1) decline in children with cystic fibrosis","volume":"14","author":"Morgan","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.jcf.2024.04.004_bib0010","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1513\/AnnalsATS.202303-245OC","article-title":"A pilot randomized clinical trial of pediatric cystic fibrosis pulmonary exacerbations treatment strategies","volume":"20","author":"Sanders","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0011","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1164\/rccm.200909-1421OC","article-title":"Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation","volume":"182","author":"Sanders","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2024.04.004_bib0012","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1164\/rccm.201610-2172OC","article-title":"Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations. eICE study results","volume":"196","author":"Lechtzin","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.04.004_bib0013","article-title":"Electronic home monitoring of children with cystic fibrosis to detect and treat acute pulmonary exacerbations and its effect on 1-year FEV(1)","author":"Yanaz","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0014","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jcf.2021.09.018","article-title":"The feasibility of home monitoring of young people with cystic fibrosis: results from CLIMB-CF","volume":"21","author":"Edmondson","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"Supplement_2","key":"10.1016\/j.jcf.2024.04.004_bib0015","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/jpids\/piac062","article-title":"The elusive role of airway infection in cystic fibrosis exacerbation","volume":"11","author":"Caverly","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0016","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2011.05.002","article-title":"Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?","volume":"10","author":"Stressmann","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.04.004_bib0017","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1513\/AnnalsATS.201211-107OC","article-title":"Changes in cystic fibrosis airway microbiota at pulmonary exacerbation","volume":"10","author":"Carmody","year":"2013","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0018","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2049-2618-1-27","article-title":"Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation","volume":"1","author":"Price","year":"2013","journal-title":"Microbiome"},{"key":"10.1016\/j.jcf.2024.04.004_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40168-015-0074-9","article-title":"The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation","volume":"3","author":"Carmody","year":"2015","journal-title":"Microbiome"},{"issue":"7","key":"10.1016\/j.jcf.2024.04.004_bib0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1164\/rccm.200309-1306OC","article-title":"Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa","volume":"169","author":"Aaron","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0021","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1378\/chest.09-1374","article-title":"Influenza-associated cystic fibrosis pulmonary exacerbations","volume":"137","author":"Ortiz","year":"2010","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.jcf.2024.04.004_bib0022","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/cid\/cix203","article-title":"Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study","volume":"64","author":"Somayaji","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2024.04.004_bib0023","article-title":"Prevalence and clinical impact of respiratory viral infections from the STOP2 study of cystic fibrosis pulmonary exacerbations","author":"Thornton","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0024","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/MCP.0b013e3283659f45","article-title":"The impact of medication adherence on lung health outcomes in cystic fibrosis","volume":"19","author":"Eakin","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"10.1016\/j.jcf.2024.04.004_bib0025","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1164\/rccm.200306-779OC","article-title":"Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis","volume":"169","author":"Goss","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0026","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12940-022-00932-1","article-title":"Assessing the health risk of living near composting facilities on lung health, fungal and bacterial disease in cystic fibrosis: a UK CF Registry study","volume":"21","author":"Khan","year":"2022","journal-title":"Environ Health"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0027","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13223-023-00760-z","article-title":"Association between cystic fibrosis exacerbations, lung function, T2 inflammation and microbiological colonization","volume":"19","author":"Albon","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"11","key":"10.1016\/j.jcf.2024.04.004_bib0028","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1513\/AnnalsATS.202111-1266OC","article-title":"Acute pulmonary exacerbation phenotypes in patients with cystic fibrosis","volume":"19","author":"Carter","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0029","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jcf.2022.12.013","article-title":"Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis","volume":"22","author":"Dong","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.004_bib0030","article-title":"Annual data report. Bethesda, Maryland: 2023","year":"2022","journal-title":"Cystic Fibrosis Foundation"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0031","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.arbres.2021.12.003","article-title":"The impact of COVID-19 in cystic fibrosis","volume":"58","author":"Flume","year":"2022","journal-title":"Arch Bronconeumol"},{"issue":"8","key":"10.1016\/j.jcf.2024.04.004_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255659","article-title":"Reduction in hospitalised COPD exacerbations during COVID-19: a systematic review and meta-analysis","volume":"16","author":"Alqahtani","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0033","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ppul.21117","article-title":"Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis","volume":"45","author":"Sanders","year":"2010","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0034","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jcf.2017.06.002","article-title":"Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor","volume":"17","author":"Flume","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.04.004_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cct.2017.11.012","article-title":"Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF","volume":"64","author":"Heltshe","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0036","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jcf.2020.08.015","article-title":"Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: a systematic review","volume":"19","author":"McLeod","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0037","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1513\/AnnalsATS.201501-021FR","article-title":"Multiple-breath washout as a lung function test in cystic fibrosis. A cystic fibrosis foundation workshop report","volume":"12","author":"Subbarao","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0038","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/thoraxjnl-2021-216928","article-title":"Longitudinal assessment of lung clearance index to monitor disease progression in children and adults with cystic fibrosis","volume":"77","author":"Horsley","year":"2022","journal-title":"Thorax"},{"issue":"160","key":"10.1016\/j.jcf.2024.04.004_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0354-2020","article-title":"The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review","volume":"30","author":"McLeod","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcf.2009.04.003","article-title":"Patient-reported respiratory symptoms in cystic fibrosis","volume":"8","author":"Goss","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcf.2020.08.006","article-title":"Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0042","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jcf.2022.06.007","article-title":"Comparative analysis of respiratory symptom scores to detect acute respiratory events in children with cystic fibrosis","volume":"22","author":"Perrem","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0043","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1378\/chest.13-0693","article-title":"Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations","volume":"144","author":"Shoki","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0044","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1513\/pats.200703-044BR","article-title":"Sputum biomarkers of inflammation in cystic fibrosis lung disease","volume":"4","author":"Sagel","year":"2007","journal-title":"Proc Am Thorac Soc"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0045","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jcf.2015.01.007","article-title":"Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients","volume":"14","author":"Waters","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.04.004_bib0046","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.acra.2020.05.008","article-title":"Comparison of functional free-breathing pulmonary (1)H and hyperpolarized (129)Xe magnetic resonance imaging in pediatric cystic fibrosis","volume":"28","author":"Couch","year":"2021","journal-title":"Acad Radiol"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0047","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02188-2018","article-title":"Hyperpolarised (129)Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis","volume":"53","author":"Rayment","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0048","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chest.2017.10.005","article-title":"CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor","volume":"153","author":"Ronan","year":"2018","journal-title":"Chest."},{"key":"10.1016\/j.jcf.2024.04.004_bib88","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02278-2023","article-title":"A randomized trial of oral prednisone for cystic fibrosispulmonary exacerbation treatment","author":"Waters","year":"2024","journal-title":"Eur Resp J"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0049","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2642","article-title":"Characterization of inpatient cystic fibrosis pulmonary exacerbations","volume":"139","author":"Cogen","year":"2017","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.jcf.2024.04.004_bib0050","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ppul.22652","article-title":"Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis","volume":"48","author":"Wagener","year":"2013","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2024.04.004_bib0051","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jcf.2019.06.008","article-title":"Predictors of pulmonary exacerbation treatment in cystic fibrosis","volume":"19","author":"Sanders","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0052","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jcf.2023.06.015","article-title":"Factors associated with lung function response with oral antibiotic treatment of pulmonary exacerbations in cystic fibrosis","volume":"22","author":"Blanchard","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0053","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jcf.2018.05.015","article-title":"Sagel SD. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis","volume":"17","author":"Hoppe","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.04.004_bib0054","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ppul.20433","article-title":"Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis","volume":"41","author":"Nazer","year":"2006","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0055","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1513\/AnnalsATS.201702-111OC","article-title":"Treatment setting and outcomes of cystic fibrosis pulmonary exacerbations","volume":"15","author":"Schechter","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0056","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jcf.2021.11.009","article-title":"Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation","volume":"21","author":"Sanders","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0057","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1183\/09031936.97.10040896","article-title":"Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects","volume":"10","author":"Wolter","year":"1997","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jcf.2024.04.004_bib0058","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1164\/rccm.201001-0057OC","article-title":"Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes","volume":"182","author":"Collaco","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.04.004_bib0059","article-title":"Annual data report. September 2023","year":"2022","journal-title":"Cystic Fibrosis Trust"},{"issue":"11","key":"10.1016\/j.jcf.2024.04.004_bib0060","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0061","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jcf.2023.02.001","article-title":"Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations","volume":"22","author":"Faino","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0062","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jcf.2022.08.001","article-title":"Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa","volume":"22","author":"Cogen","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.04.004_bib0063","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1513\/AnnalsATS.202111-1294OC","article-title":"Clinical outcomes of antipseudomonal versus other antibiotics among children with cystic fibrosis without Pseudomonas aeruginosa","volume":"19","author":"Cogen","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"10.1016\/j.jcf.2024.04.004_bib0064","article-title":"Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis","volume":"10","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.jcf.2024.04.004_bib0065","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1513\/AnnalsATS.202002-179OC","article-title":"Association of inhaled antibiotics in addition to standard intravenous therapy and outcomes of pediatric inpatient pulmonary exacerbations","volume":"17","author":"Cogen","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"9_Supplement","key":"10.1016\/j.jcf.2024.04.004_bib0066","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1128\/JCM.00580-11","article-title":"The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests","volume":"49","author":"Doern","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0067","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jcf.2019.01.008","article-title":"Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: a systematic review","volume":"18","author":"Somayaji","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.04.004_bib0068","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jcf.2019.05.012","article-title":"VanDevanter DR. The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations","volume":"18","author":"Cogen","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"9484","key":"10.1016\/j.jcf.2024.04.004_bib0069","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","article-title":"Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial","volume":"366","author":"Aaron","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcf.2024.04.004_bib0070","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2014.09.013","article-title":"Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients","volume":"14","author":"Yau","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"9459","key":"10.1016\/j.jcf.2024.04.004_bib0071","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2013the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jcf.2024.04.004_bib0072","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/phar.2842","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2024.04.004_bib0073","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528809090223","article-title":"Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?","volume":"143","author":"Watkins","year":"1988","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"11","key":"10.1016\/j.jcf.2024.04.004_bib0074","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1128\/AAC.39.11.2411","article-title":"Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa","volume":"39","author":"Weiss","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijantimicag.2015.09.014","article-title":"Antibiotic combination therapy can select for broad-spectrum multidrug resistance in Pseudomonas aeruginosa","volume":"47","author":"Vestergaard","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0076","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-3476(99)70197-6","article-title":"Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis","volume":"134","author":"Smith","year":"1999","journal-title":"J Pediatr"},{"issue":"9","key":"10.1016\/j.jcf.2024.04.004_bib0077","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/cid\/ciab525","article-title":"Association between number of intravenous antipseudomonal antibiotics and clinical outcomes of pediatric cystic fibrosis pulmonary exacerbations","volume":"73","author":"Cogen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0078","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcf.2022.04.006","article-title":"Antipseudomonal treatment decisions during CF exacerbation management","volume":"21","author":"VanDevanter","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0079","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1378\/chest.07-0843","article-title":"Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study","volume":"132","author":"Dovey","year":"2007","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2024.04.004_bib0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1513\/AnnalsATS.202203-201OC","article-title":"Systemic corticosteroids in the management of pediatric cystic fibrosis pulmonary exacerbations","volume":"20","author":"Davis","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.04.004_bib0081","article-title":"Adjunctive systemic corticosteroids for pulmonary exacerbations of cystic fibrosis","author":"McElvaney","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0082","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ppul.25204","article-title":"Evaluation of rescue oral glucocorticoid therapy during inpatient cystic fibrosis exacerbations","volume":"56","author":"Muirhead","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2024.04.004_bib0083","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ppul.26362","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on bacterial cultures from people with cystic fibrosis","volume":"58","author":"Beck","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.jcf.2024.04.004_bib0084","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jcf.2020.02.012","article-title":"Finding the relevance of antimicrobial stewardship for cystic fibrosis","volume":"19","author":"Cogen","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"Supplement_2","key":"10.1016\/j.jcf.2024.04.004_bib0085","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1093\/jpids\/piac071","article-title":"Antimicrobial stewardship in cystic fibrosis","volume":"11","author":"Lloyd","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"8","key":"10.1016\/j.jcf.2024.04.004_bib0086","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1017\/ice.2017.94","article-title":"Development and application of an antibiotic spectrum index for benchmarking antibiotic selection patterns across hospitals","volume":"38","author":"Gerber","year":"2017","journal-title":"Infect Control Hosp Epidemiol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932400047X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932400047X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:10:16Z","timestamp":1783019416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932400047X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S156919932400047X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.04.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}